Stifel Nicolaus analyst James Condulis maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $80.00.

A rumor regarding Cytokinetics (CYTK) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, ...

Cytokinetics (NASDAQ:CYTK – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Thursday,Benzinga reports.

Morgan Stanley has upgraded Cytokinetics (NASDAQ:CYTK) to overweight from equal weight while lowering its price target, adding that the stock's risk/reward has skewed to the upside. The bank noted ...

Cytokinetics, Incorporated has a 52-week low of $40.53 and a 52-week high of $81.36. The company has a fifty day moving average price of $47.61 and a 200-day moving average price of $51.96.

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

Most outdoor brand logos are bland as a soggy sandwich left out in the rain. But not Patagonia's. Their logo is like a breath of fresh mountain air in a world of corporate stuffiness. I remember the ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.